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Abstract
Fetal hemoglobin (HbF), encoded by the HBG2 and HBG1 genes, is the best-known genetic modulator of sickle cell anemia, 
varying dramatically in concentration in the blood of these patients. This variation is partially associated with polymorphisms 
located in the promoter region of the HBG2 and HBG1 genes. In order to explore known and unknown polymorphisms in these 
genes, the sequences of their promoter regions were screened in sickle cell anemia patients and correlated with both their HbF 
levels and their βS-globin haplotypes. Additionally, the sequences were compared with genes from 2 healthy groups, a reference 
one (N = 104) and an Afro-descendant one (N = 98), to identify polymorphisms linked to the ethnic background.The reference 
group was composed by healthy individuals from the general population. Four polymorphisms were identified in the promoter 
region of HBG2 and 8 in the promoter region of HBG1 among the studied groups. Four novel single nucleotide polymorphisms 
(SNP) located at positions -324, -317, -309 and -307 were identified in the reference group. A deletion located between -396 
and -391 in the HBG2 promoter region and the SNP -271 C→T in the HBG1 promoter region were associated with the Central 
African Republic βS-globin haplotype. In contrast, the -369 C→G and 309 A→G SNPs in the HBG2 promoter region were cor-
related to the Benin haplotype. The polymorphisms -396_-391 del HBG2, -369 SNP HBG2 and -271 SNP HBG1 correlated with 
HbF levels. Hence, we suggest an important role of HBG2 and HBG1 gene polymorphisms on the HbF synthesis. 
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Introduction
Clinical heterogeneity is an important characteristic of sickle cell anemia (SCA) and other hemoglobinopathies (1). The 
molecular data regarding diseases comprise the target gene and a large number of known and unknown DNA changes. 
These alterations concomitantly modify the expression of several genes, including the gamma globin genes (HBG2 and 
HBG1), responsible for the synthesis of the γ chains present in fetal hemoglobin (HbF) (2-4). Gene expression is modu-
lated by a large number of polymorphisms located in the β-globin gene cluster. Of these, the HBG2 -158 C→T variation 
is consistently linked with an increase of HBG2 expression in cis, which are DNA sequences in the vicinity of the struc-
tural portion of a gene that are required for gene expression (5). Thus, there are cis-acting sequences that behave both 
positively and negatively in transcriptional regulation. For this reason, many studies have focused on learning about the www.bjournal.com.br Braz J Med Biol Res Online Provisional Version
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reactivation of the dormant HBG genes during adulthood and in understanding which cis-acting elements govern HbF 
synthesis. The regulatory sequences 5’ of HBG2 and HBG1 harbor at least eight polymorphic markers. These include the 
4-bp deletion (AGCA) at positions -225 to -222 upstream of HBG1 (2) and the HBG2 -157 C→T single nucleotide poly-
morphism (SNP), which has been reported to be associated with high HbF levels (6). Moreover, some of the HBG2 and 
HBG1 polymorphisms are associated with the major βS-globin gene haplotypes, which are named Benin (Ben), Central 
African Republic (CAR), Senegal (Sen), Arab-Indian and Cameroon (Cam), according to their geographical origin and 
the ethnic groups in which they are frequently found (1,7). For example, there is a T→A variation in the HBG1 promoter 
region (-499) that is associated with the Ben haplotype among Sicilian and North American individuals (8). Because 
of the wide variability in clinical expression, and the consistent differences in HbF levels among SCA patients with dif-
ferent haplotypes, we have initiated sequence analyses of the HBG2 and HBG1 promoter regions in order to identify 
differences that may be important for understanding the variations in γ-chain synthesis. The 5’ promoter regions were 
chosen because of their potential regulatory role in gene expression. These regions are known to contain both positive 
(enhancer) and negative (silencer) regulatory elements upstream of the consensus promoter sequences (9). We report 
here sequence data for these regions of both HBG2 and HBG1 from different Brazilian groups, i.e., SCA patients and 
two healthy groups, a reference one and an Afro-descendant one. 
Patients and Methods
Patients and control subjects 
Blood samples were collected from 152 SCA patients, 104 apparently healthy individuals randomly chosen from the 
general population (reference group) and 98 Afro-descendant individuals. The SCA patients have been followed at the 
Hematology and Hemotherapy Bahia Foundation and were selected between 2004 and 2005. The median age (± SD) 
of this group of 73 women and 79 men was 10.7 ± 11.2 years.
The reference group consisted of volunteers (employed or their children) with a median age of 9.7 ± 12.2 years, 54 
men and 50 women who went to the Faculty of Pharmacy of the Federal University of Bahia for laboratory analyses 
and who showed an AA hemoglobin profile. The SCA patient group and the reference group are from Bahia, Northeast 
region of Brazil, which has both the highest frequency of abnormal hemoglobin and the highest rate of race admixture, 
mainly of individuals of African, European and Amerindian origin (10). 
The Afro-descendant group, from the Saracura and Arapema communities, is located in Pará, Brazil. This group 
consisted of 51 men and 47 women with a median age of 66 ± 14.1 years. In contrast to the SCA and reference groups, 
the Afro-descendant group derives from a slave community located in Pará, Northern Brazil, where the race admixture 
is lower, composed basically of individuals of African origin (11).
Individuals who reported any disease were excluded from the reference and the Afro-descendant groups. 
The study was approved by the Human Subject Research Ethics Committee of the Oswaldo Cruz Research Founda-
tion in Bahia (process No. 0025.0.0225.000-07) and Amazonia (process No. 209/03). Informed consent was obtained 
from the parents or guardians.
DNA analyses
Genomic DNA was isolated from peripheral blood leukocytes using the QIAMP DNA Blood Kit (Qiagen, USA) ac-
cording to manufacturer protocols. The HBG2 and HBG1 promoter regions were sequenced (12) with an ABI Prism 3100 
DNA sequencer using Kit BigDye 03 Terminator TM Sequencing Standards (Applied Biosystems, USA) and specific 
sequencing primers: 5’-TGA AAC TgT ggT CTT TAT gAA AAT Tg-3’ forward HBG1, 5’-gCA CTg AAA CTg AAA CTg TTg 
CTT TAT Agg AT-3’ forward HBG2, and 5’-ggC gTC Tgg ACT Agg AgC TTA TTg-3’ reverse for both genes. The βS-globin 
gene haplotypes were identified in the SCA patients by the polymerase chain reaction and by restriction fragment length 
polymorphism techniques (13). 
Statistical analyses
Descriptive analyses included gene and allelic frequencies, odds ratio as an estimate of relative risk and the 95% 
confidence interval (CI). The chi-square test was used to associate independent categorical variables and to test for 
the Hardy-Weinberg equilibrium. The level of significance was set at P < 0.05. All analyses were carried out using the 
Epi-Info software, version 6.04.www.bjournal.com.br Braz J Med Biol Res Online Provisional Version
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Results
HBG2 and HBG1 promoter region polymorphisms 
Table 1 shows the frequencies of the HBG2 and HBG1 promoter region polymorphisms in the two target groups and 
in the reference group. Each polymorphism was either a deletion or an SNP, and their frequencies were consistent with 
the Hardy-Weinberg equilibrium (Table 1) except the -396_-391 del, -369 C→G and -157 T→C of the Afro-descendant 
group, which was not calculated because there was only one genotype for each polymorphism. We identified four poly-
morphisms in the HBG2 promoter, which were located at positions -396 to -391, -369, -309, and -157. Additionally, we 
identified eight polymorphisms in the HBG1 promoter, located at -398, -369, -225 to -222, -271, -324, -317, -309, and 
-307. All polymorphisms showed a more homogeneous distribution pattern in the Afro-descendant group compared with 
the SCA and reference groups. 
When we compared the frequencies of these polymorphisms between the SCA and reference groups, who are sup-
posed to have similar genetic and environmental backgrounds, we found some interesting differences (Table 2). The 
6-bp deletion located between -396 and -391 of the HBG2 promoter region was three times more frequent among SCA 
patients than in the reference group. Moreover, the other HBG2 promoter polymorphisms showed a higher frequency of 
mutant alleles among SCA patients, which were the SNPs -369 C→G, -309 A→G and -157 T→C. 
The frequencies of the 4-bp deletion located at -225 to -221 and of the SNPs -398 G→A and -369 C→G of HBG1 
were similar for the SCA and reference groups. On the other hand, the T allele for the 271 SNP was more frequent in 
the SCA group. 
New polymorphisms identified in the reference group
We identified four new polymorphisms in the HBG1 promoter region, which were SNPs located at positions -324 
(C→T), -317 (A→G), -309 (A→G), and -307 (G→A) (GeneBank Bankit #1186662). Interestingly, they were found together 
in a heterozygous pattern within three individuals from the reference group. 
The polymorphisms -396_-391 del and -369 SNP in the HBG2 promoter are associated with the -271 HBG1 
SNP and the -309 SNP HBG2, respectively
The chance of finding the mutant allele of the -271 HBG1 SNP in patients who had the HBG2 -396_-391 deletion was 
20 times higher than in patients who did not have it. The same was true when we combined the -369 and -309 HBG2 
SNPs, but the chance decreased approximately 6-fold in this case. The SCA patients who had the -396_-391 deletion 
within HBG2 showed a lower chance of having the associated -369 or -309 HBG2 SNP, with an odds ratio of 0.07 (95%CI 
= 0.03-0.17) or 0.14 (95%CI = 0.06-0.31), respectively. Similarly, the possibility of finding the -309 HBG2 and the -271 
HBG1 SNPs together was dramatically lower than the possibility of finding each SNP alone (Table 3).
 
The polymorphisms HBG2 -396_-391 del and -271 HBG1 SNP are associated with CAR βS-globin gene 
haplotype
The frequencies of the βS-globin gene haplotypes were analyzed in 144 patients, and we found 58 (40.3%) with 
genotype CAR/Ben, 43 (30%) with Ben/Ben, 32 (22.2%) with CAR/CAR, 4 (2.8%) with Ben/Sen, 4 (2.8%) with Ben/
Atypical, 2 (1.4%) with Ben/Cam, and 1 (0.7%) with CAR/Cam. The CAR haplotype was strongly associated with the 
HBG2 -396_-391 deletion and with the mutant allele for the -271 HBG1 SNP (Table 4). However, one CAR/CAR patient 
did not have the mutant allele for the -271 HBG1 SNP. Among the heterozygous haplotypes, there were only one CAR/
Cam and 27 CAR/Ben with the HBG2 -396_-391 deletion. The mutant allele for the -271 HBG1 SNP was present in 21 
CAR/Ben patients, but not in other heterozygous haplotypes. 
The polymorphisms -369 and -309 SNP in HBG2 are associated with the Ben βS-globin gene haplotype
The mutant alleles for the -369 and -309 HBG2 gene SNP were found in patients with the Ben haplotype. Table 4 3 
shows Ben chromosomes in association with these SNP. Among subjects who had the mutant allele for the -369 HBG2 
SNP, 41 were Ben/Ben, 27 CAR/Ben, 2 Ben/Sen, 2 Ben/Atypical, and 1 CAR/Cam. In addition, the mutant allele for the 
-309 HBG2 SNP was present in 43 Ben/Ben, 35 CAR/Ben, 4 Ben/Atypical, 3 Ben/Sen, and 2 Ben/Cam subjects. On the 
other hand, 1 CAR/CAR patient was heterozygous for the -369 HBG2 SNP. www.bjournal.com.br Braz J Med Biol Res Online Provisional Version
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The polymorphisms -396_-391 del HBG2, -369 SNP HBG2 and -271 SNP HBG1 are associated with HbF levels
In order to determine a possible relationship of the HBG2 and HBG1 polymorphisms with HbF levels, we classified 
the patients into four groups according to their HbF levels (Table 5). Most of the patients who did not have the -396_-391 
HBG2 deletion showed HbF >5.0%. The presence of the wild-type allele for the -271 HBG1 SNP and the mutant allele for 
the -369 HBG2 SNP was associated with patients who had HbF levels >5.0%. The -309 HBG1 SNP and the remaining 
polymorphisms identified did not show any association with HbF levels (data not shown). 
Discussion
The present study has identified both previously described and new HBG2 and HBG1 polymorphisms in three different 
population groups. It was believed that four of these polymorphisms may be important to SCA patients because of their 
apparent association with HbF levels and with the βS-globin gene haplotypes. Moreover, all polymorphisms were found 
to have a more homogeneous pattern of distribution in the Afro-descendant group, which consisted of individuals with a 
lower rate of racial admixture. This group was formed by descendants of two African slave populations living in Northern 
Brazil, a different region from that of the other two groups. Historical data suggest that about 90% of the slaves brought 
to Northern Brazil were from Angola, Congo and Mozambique (14). Both the SCA group and the reference group were 
from Bahia, Brazil, and both were composed of individuals with high rates of racial admixture. An estimated rate of 97% 
interethnic panmixia has been shown in Bahia, possibly due to the intensive African slave trade during which more than 
five million people from several African countries were brought to Brazil between 1550 and 1850, mainly between the 
18th and 19th centuries (15). Moreover, Bahia was the only Brazilian State that restricted slave traffic through Ecuador, a 
fact that explains the correlation between genotype frequencies found in Bahia and Western Africa, principally the Bay of 
Benin region (10). These facts may explain the different frequencies of all polymorphisms found in the present study. 
When we compared the polymorphisms of the HBG2 and HBG1 genes between the SCA group and the reference 
groups we found five of them with a different distribution in their genotypes. Since both groups have had similar genetic 
and environmental backgrounds, it was believed that these differences could be related to the βS chromosomes. Thus, 
the -396_-391 deletion and the -369 C→G and -309 A→G SNPs in the HBG2 promoter might be associated with the 
polymorphic sites linked to the βS haplotypes before the occurrence of this mutation. Although the age of the βS-globin 
gene mutation is not known with certainty, expansion of the mutation probably occurred in parallel to malaria, a strong 
selective factor, becoming endemic on the African continent (16). The -157 HBG2 SNP was recently described in SCA 
patients from the same region of Brazil, and it was suggested that the C allele at this position may be related to HbF 
levels (6). In contrast to the report of Adorno et al. (6), we found that 100% of healthy Afro-descendant individuals and 
about 90% of the SCA and reference group subjects had the variant allele for the -157 HBG2 SNP. Hence, this SNP 
seems to be simply an ethnic marker, and may not be related to HbF levels. 
The -271 C→T SNP in the HBG1 promoter has been described in previous reports (2,16) to be exclusively located in 
βS chromosomes. However, in the present study, this SNP was also present among the reference and Afro-descendant 
groups. All 5 Afro-descendant individuals who had the T allele (mutant) were heterozygous for the βS mutation. On the 
other hand, 19 βA individuals from the reference group had this mutant allele instead of the C, which may be a result of 
a crossing over event between two heterozygous individuals for the βS mutation. Additionally, the SNP in HBG1 may be 
considered a gene conversion of a βS CAR haplotype because of HBG2-like sequences between bases -306 and -271 
and extending to bases 25-1107, which have replaced the corresponding HBG1 sequence (17).
The four new SNPs in the HBG1 promoter (-324 C→T, -317 A→G, -309 A→G and -307 G→A) identified in the refer-
ence group may have origins in Europe or among the Amerindians since they were not found in the two other groups 
studied. Studies are necessary to confirm this explanation and to determine the genetic impact of these polymorphisms 
on HBG1 expression. 
When the odds of finding the -396_-391 deletion in HBG2 together with the -271 HBG2 SNP were measured, a 
strong association between these two polymorphisms was identified. There was also an important association between 
the -369 and -309 SNPs in HBG2. These facts may indicate a similar origin of these closely associated polymorphisms 
or a possible association with the βS-globin haplotypes.
The major sequence differences in the HBG2 promoter region are in the βS chromosomes with the haplotypes CAR 
(-396_-391 deletion) and Ben (-369 and -309 SNPs). In addition, the -271 SNP in the HBG1 promoter was also strongly 
associated with CAR chromosomes. Only one CAR/CAR patient did not show this association, and our results are dif-
ferent from those obtained in previous studies (2,16) in which the investigators did not detect any non-CAR haplotype 
associated with the mutant allele for the -271 SNP in HBG1. This difference may be explained by multiple recombinations 
between heterozygous CAR and Ben haplotypes.
Finally, we stratified the SCA patients into two groups according to HbF levels to investigate the correlation between www.bjournal.com.br Braz J Med Biol Res Online Provisional Version
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these levels and the polymorphisms -396_-391 del HBG2, -369 SNP HBG2, -309 SNP HBG2 and -271 SNP HBG1, 
as shown in Table 5. Most of patients who did not have the -396_-391 del in the HBG2 gene had HbF levels >5.0 (P < 
0.0001). The absence of the mutant allele (T) for the -271 SNP in the HBG1 gene also correlated with higher HbF levels 
(P < 0.0001). Conversely, the presence of the mutant allele (G) for the -369 SNP in the HBG2 gene correlated with higher 
levels of HbF (P = 0.006). The other polymorphisms did not show any relationship with HbF levels. These results are 
different from those reported by Bouhassira et al. (17) and by Lanclos et al. (2), but both groups of patients previously 
studied were African-American who had a genetic background different from the Brazilian SCA patients. Moreover, these 
gene polymorphisms may be part of other molecular events that act synergistically on HbF expression.
Five patients were excluded from these analyses because they were younger than 6 years and this fact may have 
influenced the results. At birth, HbF represents 80–90% of the total hemoglobin synthesized and gradually decreases to 
1% by 10 months in normal infants, but not in SCA children, who may have higher HbF levels up to the age of 6 years 
(18). 
Further studies will be necessary to clarify the complex interaction between these specific sequences and certain 
trans-activating factors within specific developmental stages of erythroid cells and its possible impact on the clinical 
outcome of SCA patients. 
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Table 1. Frequencies of polymorphisms in the HBG2 and HBG1 promoter regions of patients with sickle cell anemia (SCA), of individu-
als from the reference group and of Brazilian Afro-descendants.
Position (genotype) SCA patients (N = 152) Reference group (N = 104) Afro-descendant group (N = 98)
HBG2 -396_-391 del
ND/ND  90 (59.2) 96 (92.3) 98 (100)
ND/D 50 (32.9) 8 (7.7) 0
D/D 12 (7.9) 0 0
HBG2 -369 SNP
C/C 75 (49.3) 80 (76.9) 98 (100)
G/C 60 (39.5) 23 (22.1) 0
G/G 17 (11.2) 1 (1.0) 0
HBG2 -309 SNP
A/A 59 (38.8) 79 (76.0) 95 (96.9)
A/G 65 (42.8) 22 (21.2) 3 (3.1)
G/G 28 (18.4) 3 (2.9) 0
HBG2 -157 SNP
T/T 0 15 (14.4) 0
T/C 4 (2.6) 47 (45.2) 0
C/C 148 (97.4) 42 (40.4) 98 (100)
HBG1 -398 SNP
G/G 126 (82.9) 98 (94.2) 95 (96.9)
G/A 25 (17.1) 6 (5.8) 3 (3.1)
A/A 0 0 0
HBG1 -369 SNP
C/C 2 (1.3) 3 (2.9) 0
C/G 26 (17.1) 23 (22.1) 2 (2.0)
G/G 124 (81.6) 78 (75.0) 96 (98.0)
HBG1 -271 SNP
C/C 98 (64.5) 85 (81.7) 93 (94.9)
C/T 44 (28.9) 18 (17.3) 5 (5.1)
T/T 10 (6.6) 1 (1.0) 0
HBG1 -225_-221 del
ND/ND  135 (88.8) 82 (78.8) 66 (67.3)
ND/D 17 (11.2) 20 (19.2) 30 (30.6)
D/D 0 2 (1.9) 2 (2.0)
Data are reported as number wiith percent in parentheses. All HBG1 and HBG2 polymorphisms were in Hardy-Weinberg equilibrium 
(chi-square test) except -396_-391 del, -369 C→G and -157 T→C in the HBG2 gene of the Afro-descendant group, which could not be 
calculated. D = deletion; ND = no deletion; SNP = single nucleotide polymorphism. www.bjournal.com.br Braz J Med Biol Res Online Provisional Version
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Table 2. Differences of HBG2 and HBG1 polymorphisms between patients with sickle cell anemia, and 
the reference group.
Polymorphism SCA patients (N = 152)  Reference group (N = 104) OR (95%CI)
HBG2 -396_-391 del 27* 4 2.98 (1.83-15.9)
HBG2 -369 SNP (allele G) 47** 13 1.08 (1.6-6.15)
HBG2 -309 SNP (allele G) 60** 14 1.39 (2.18-8.03)
HBG2 -157 SNP (allele C) 150** 66 31.8 (10.1-184.0)
HBG1 -398 SNP (allele A) 13* 3 2.05 (0.87-11.3)
HBG1 -369 SNP (allele G) 137 89 0.60 (0.51-3.3)
HBG1 -271 SNP (allele T) 32** 10 1.36 (1.1-1.67)
HBG1 -225_-221 del 8 12 0.2 (0.17-1.08)
SNP = single nucleotide polymorphism. *P < 0.05 compared to reference group (Fisher test); **P < 0.05 
compared to reference group (Yates-corrected χ2 test).
Table 3. Association of polymorphisms in the HBG2 and HBG1 promoter region of patients with sickle cell anemia (SCA, 
N = 152).
-271 HBG1 (TC + TT), N -309 HBG2 (GA + GG), N -369 HBG2 (CG + GG), N
-396_-391 del HBG2 (D/D + D/ND) 45 17 15
OR/95%CI 23.8 (9.02-65.0) 0.07 (0.03-0.17) 0.14 (0.06-0.31)
P <0.001* <0.001* <0.001*
-369 HBG2 (CG + GG) 9 63
OR/95%CI 0.09 (0.03-0.22) 6.75 (3.01-15.3)
P <0.001* <0.001*
-309 HBG2 (GA + GG) 13
OR/95%CI 0.07 (0.03-0.17)
P <0.001*
 
*Yates-corrected χ2 test.www.bjournal.com.br Braz J Med Biol Res Online Provisional Version
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Table 4. Association of the βS-globin gene genotypes with the -396_-391 del HBG2, -369 HBG2, -309 HBG2, 
and -271 HBG1 polymorphisms in patients with sickle cell anemia (N = 110).
Polymorphism CAR (N = 62) OR (95%CI) P* Ben (N = 82) OR (95%CI) P*
-396_-391 del HBG2
D/D + D/ND 46 14.8 (6.07-37.0) <0.001 14 0.09 (0.04-0.21) <0.001
ND/ND 16 68
-271 HBG1
TC + TT 42 11.7 (4.57-3.08) <0.001 11 0.11 (0.04-0.25) <0.001
CC 19 66
-369 HBG2
CG + GG 15 0.13 (0.06-0.29) <0.001 57 7.29 (3.30-16.3) <0.001
CC 47 23
-309 HBG2
GA + GG 17 0.07 (0.03-0.17) <0.001 65 11.9 (4.94-29.3) <0.001
AA 44 12
CAR = Central African Republic; BEN = Benin. *Yates-corrected χ2 test.
Table 5. Association of fetal hemoglobin (HbF) levels with the -396_-391 del 
HBG2, -369 HBG2, -309 HBG2, and -271 HBG1 polymorphisms in patients with 
sickle cell anemia (N = 147).
Polymorphism HbF levels  OR (95%CI) P*
≤5.0% >5.0%
-396_-391del HBG2
D/D + D/ND 26 (44.1) 33 (55.9) 3.83 (1.79-8.17) <0.0001
ND/ND 15 (17.0) 73 (83.0)
-369 HBG2
CG + GG 13 (17.3) 62 (82.7) 0.32 (0.15-0.70) 0.006
CC 28 (38.9) 44 (61.1)
-309 HBG2
GA + GG 20 (22.0) 71 (78.0) 0.46 (0.22-0.97) 0.07
AA 21 (37.5) 35 (62.5)
-271 HBG1
TC + TT 25 (49.0) 26 (51.0) 4.80 (2.23-10.3) <0.0001
CC 16 (16.7) 80 (83.3)
Data are reported as number with percent in parentheses. *Yates corrected χ2 
test.